Zobrazeno 1 - 3
of 3
pro vyhledávání: '"David Solub"'
Autor:
Jean-Philippe Jacquin, Lionel Uwer, Alexia Savignoni, Jean-Marc Ferrero, Alain Lortholary, David Solub, Flore Delaporte, Nassera Chalabi, Sophie Pibre, Yazid Belkacemi
Publikováno v:
Breast, Vol 49, Iss , Pp 1-7 (2020)
Objectives: HERmione study was conducted to assess, in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC), the safety profile of subcutaneous (SC) formulation of trastuzumab in real-life in France. Materials and method
Externí odkaz:
https://doaj.org/article/7b1c3468ff47463cbb95c532b85fbf2b
Autor:
Pierre-Emmanuel Stoebner, Christophe Bedane, A. Jannic, Marc Dumas, Marie Moncourier, Sandrine Mansard, Anne-Bénédicte Duval-Modeste, David Solub, Sophie Darras, Suzanne Devaux, Julia Sanchez, Nicolas Meyer, Laurent Misery, Valentine Heidelberger, Raoul Triller, Ingrid Kupfer-Bessaguet, Nathalie Beneton, Florence Brunet-Possenti, Gaëlle Quéreux, E. Maubec, Sophie Dalac, François Skowron, Safia Abed, Caroline Gaudy-Marqueste, Laurent Mortier, Monica Dinulescu, F. Herms, Lucie Peuvrel, Marouane Boubaya, Candice Hober, Pierre Guillet, Mahtab Samimi, Yves Reguerre, Nicolas Poulalhon, Anne Pham-Ledard, Stéphanie Catala, Eve-Marie Neidhardt, Romain Lesbazeilles, Jean-Philippe Arnault, Brigitte Dréno, Olivier Collard, Philippe Celerier, Julie De Quatrebarbes, Youssef Tazi, Pierre Combe, Caroline Jacobzone, Élodie Archier, F. Aubin, Dominique Spaeth, Clémence Berthin, Nora Kramkimel, Florent Grange, Candice Lesage, Lisa Fredeau, A. Schoeffler, Marc Pracht, Bertille Bonniaud, Laure Cesaire, Maxime Etienne, Olivier Lauche
Publikováno v:
Cancers
Cancers, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Cancers, Vol 13, Iss 3547, p 3547 (2021)
Cancers, MDPI, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Volume 13
Issue 14
Cancers, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Cancers, Vol 13, Iss 3547, p 3547 (2021)
Cancers, MDPI, 2021, 13 (14), 14 p. ⟨10.3390/cancers13143547⟩
Volume 13
Issue 14
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc71b63af8c9862b6ab08fc449cfdcd5
https://hal.inrae.fr/hal-03332168
https://hal.inrae.fr/hal-03332168
Autor:
Cedric Lecaille, Julien Taieb, Christelle De La Fouchardiere, Mélanie Gauthier, Jean-Frédéric Blanc, Anne Thirot-Bidault, David Malka, Franck Carbonnel, Lysiane Marthey, David Solub, Eric Francois, Romain Coriat, Isabelle Trouilloud, Jean-Baptiste Bachet, Antonio Sa-Cunha, Sylvain Manfredi, Eric Terrebonne, Adèle Cueff
Publikováno v:
Annals of Oncology. 24:iv12
Background The FOLFIRINOX regimen improves survival when compared to gemcitabine as first line treatment for patients (pts) with metastatic pancreatic cancer (1). There is no such data in non resecable, non metastatic, locally advanced pancreatic ade